{"pmid":32294265,"title":"Psoriasis health care in the time of the coronavirus pandemic: insights from dedicated centers in sardinia (Italy).","text":["Psoriasis health care in the time of the coronavirus pandemic: insights from dedicated centers in sardinia (Italy).","Psoriasis is a major chronic inflammatory skin disease, affecting about 3% of the population in Italy, whose management require experienced specialists in order to guarantee high-quality standards of care. The pandemic coronavirus (2019-nCoV; COVID-19) has changed the approach to all patients requiring close contact during a visit, including dermatologic consultations. In Italy, true outbreak begun in Lombardy, by February 21, 2020 with exponential contagion, surpassing China in the number of deaths.","J Eur Acad Dermatol Venereol","Atzori, L","Mugheddu, C","Addis, G","Sanna, S","Satta, R","Ferreli, C","Atzori, M G","Montesu, M A","Rongioletti, F","32294265"],"abstract":["Psoriasis is a major chronic inflammatory skin disease, affecting about 3% of the population in Italy, whose management require experienced specialists in order to guarantee high-quality standards of care. The pandemic coronavirus (2019-nCoV; COVID-19) has changed the approach to all patients requiring close contact during a visit, including dermatologic consultations. In Italy, true outbreak begun in Lombardy, by February 21, 2020 with exponential contagion, surpassing China in the number of deaths."],"journal":"J Eur Acad Dermatol Venereol","authors":["Atzori, L","Mugheddu, C","Addis, G","Sanna, S","Satta, R","Ferreli, C","Atzori, M G","Montesu, M A","Rongioletti, F"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294265","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jdv.16473","keywords":["COVID-19","Coronavirus pandemic","dermatology","psoriasis"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["Italy","Italy","Lombardy","China","sardinia","Italy"],"countries":["China","Italy"],"countries_codes":["CHN|China","ITA|Italy"],"_version_":1664266295678337025,"score":8.233237,"similar":[{"pmid":32300516,"pmcid":"PMC7160052","title":"Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times.","text":["Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times.","With the emergence of the novel coronavirus disease (COVID-19) viral pandemic, there is uncertainty whether biologic agents for psoriasis may place patients at a higher risk for infection or more severe disease course. This commentary offers patient counseling recommendations based on the current available evidence. While there are currently no specific data for psoriasis biologics and COVID-19, data are presented here from phase III clinical trials of psoriasis biologics on rates of upper respiratory infection, influenza, and serious infection. Overall these data reveal that on the whole, psoriasis biologics do not show major increases in infection risk compared to placebo during the course of these trials. However, as the COVID-19 virus is a novel pathogen that is associated with mortality in a subset of patients, a cautious approach is warranted. We discuss factors that may alter the benefit-risk ratio of biologic use during this time of COVID-19 outbreak. Ultimately, treatment decisions should be made on the basis of dialogue between patient and provider, considering each patient's individualized situation. Once this pandemic has passed, it is only a matter of time before a new viral disease reignites the same issues discussed here.","Dermatol Ther (Heidelb)","Brownstone, Nicholas D","Thibodeaux, Quinn G","Reddy, Vidhatha D","Myers, Bridget A","Chan, Stephanie Y","Bhutani, Tina","Liao, Wilson","32300516"],"abstract":["With the emergence of the novel coronavirus disease (COVID-19) viral pandemic, there is uncertainty whether biologic agents for psoriasis may place patients at a higher risk for infection or more severe disease course. This commentary offers patient counseling recommendations based on the current available evidence. While there are currently no specific data for psoriasis biologics and COVID-19, data are presented here from phase III clinical trials of psoriasis biologics on rates of upper respiratory infection, influenza, and serious infection. Overall these data reveal that on the whole, psoriasis biologics do not show major increases in infection risk compared to placebo during the course of these trials. However, as the COVID-19 virus is a novel pathogen that is associated with mortality in a subset of patients, a cautious approach is warranted. We discuss factors that may alter the benefit-risk ratio of biologic use during this time of COVID-19 outbreak. Ultimately, treatment decisions should be made on the basis of dialogue between patient and provider, considering each patient's individualized situation. Once this pandemic has passed, it is only a matter of time before a new viral disease reignites the same issues discussed here."],"journal":"Dermatol Ther (Heidelb)","authors":["Brownstone, Nicholas D","Thibodeaux, Quinn G","Reddy, Vidhatha D","Myers, Bridget A","Chan, Stephanie Y","Bhutani, Tina","Liao, Wilson"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32300516","week":"202016|Apr 13 - Apr 19","doi":"10.1007/s13555-020-00377-9","keywords":["biologics","covid-19","coronavirus","infection","pandemic","psoriasis","sars-cov-2"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664357978581499904,"score":117.37815},{"pmid":32178769,"pmcid":"PMC7102589","title":"COVID-19 and Italy: what next?","text":["COVID-19 and Italy: what next?","The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already taken on pandemic proportions, affecting over 100 countries in a matter of weeks. A global response to prepare health systems worldwide is imperative. Although containment measures in China have reduced new cases by more than 90%, this reduction is not the case elsewhere, and Italy has been particularly affected. There is now grave concern regarding the Italian national health system's capacity to effectively respond to the needs of patients who are infected and require intensive care for SARS-CoV-2 pneumonia. The percentage of patients in intensive care reported daily in Italy between March 1 and March 11, 2020, has consistently been between 9% and 11% of patients who are actively infected. The number of patients infected since Feb 21 in Italy closely follows an exponential trend. If this trend continues for 1 more week, there will be 30 000 infected patients. Intensive care units will then be at maximum capacity; up to 4000 hospital beds will be needed by mid-April, 2020. Our analysis might help political leaders and health authorities to allocate enough resources, including personnel, beds, and intensive care facilities, to manage the situation in the next few days and weeks. If the Italian outbreak follows a similar trend as in Hubei province, China, the number of newly infected patients could start to decrease within 3-4 days, departing from the exponential trend. However, this cannot currently be predicted because of differences between social distancing measures and the capacity to quickly build dedicated facilities in China.","Lancet","Remuzzi, Andrea","Remuzzi, Giuseppe","32178769"],"abstract":["The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already taken on pandemic proportions, affecting over 100 countries in a matter of weeks. A global response to prepare health systems worldwide is imperative. Although containment measures in China have reduced new cases by more than 90%, this reduction is not the case elsewhere, and Italy has been particularly affected. There is now grave concern regarding the Italian national health system's capacity to effectively respond to the needs of patients who are infected and require intensive care for SARS-CoV-2 pneumonia. The percentage of patients in intensive care reported daily in Italy between March 1 and March 11, 2020, has consistently been between 9% and 11% of patients who are actively infected. The number of patients infected since Feb 21 in Italy closely follows an exponential trend. If this trend continues for 1 more week, there will be 30 000 infected patients. Intensive care units will then be at maximum capacity; up to 4000 hospital beds will be needed by mid-April, 2020. Our analysis might help political leaders and health authorities to allocate enough resources, including personnel, beds, and intensive care facilities, to manage the situation in the next few days and weeks. If the Italian outbreak follows a similar trend as in Hubei province, China, the number of newly infected patients could start to decrease within 3-4 days, departing from the exponential trend. However, this cannot currently be predicted because of differences between social distancing measures and the capacity to quickly build dedicated facilities in China."],"journal":"Lancet","authors":["Remuzzi, Andrea","Remuzzi, Giuseppe"],"date":"2020-03-18T11:00:00Z","year":2020,"_id":"32178769","week":"202012|Mar 16 - Mar 22","doi":"10.1016/S0140-6736(20)30627-9","link_comment_in":"32220279","source":"PubMed","locations":["Italy","China","Hubei","Italian"],"countries":["China","Italy"],"countries_codes":["CHN|China","ITA|Italy"],"topics":["Epidemic Forecasting"],"weight":1,"_version_":1663352133880119296,"score":116.08611},{"pmid":32275256,"title":"Vademecum for the treatment of people with COVID-19. Edition 2.0, 13 March 2020.","text":["Vademecum for the treatment of people with COVID-19. Edition 2.0, 13 March 2020.","The spread of COVID-19 epidemic in Italy, and particularly in Lombardy determined the need to standardize the therapeutic approach in order to offer the same indications for all hospitals in Lombardy. However, no specific drug has been previously approved for the COVID-19 treatment. The Lombardy Section of the Italian Society of Infectious and Tropical Diseases provided this <<vademecum>> with the aim to explore the current evidence about the drugs likely to be efficacious in the treatment of COVID-19. Moreover, a multidisciplinary group including critical care specialists has been created in order to provide indications about supporting measures and the use of steroids. A new grading scale has been proposed to help patients' stratification according to the severity of the respiratory conditions. Lastly, a collaborating group with immunologists and rheumatologists has been built with the aim of providing some guidance about the use of tocilizumab, a promising option for the treatment of the hyperinflammatory state occurring in most patients affected by COVID-19.","Infez Med","Lombardy Section Italian Society Infectious And Tropical Diseases, -","32275256"],"abstract":["The spread of COVID-19 epidemic in Italy, and particularly in Lombardy determined the need to standardize the therapeutic approach in order to offer the same indications for all hospitals in Lombardy. However, no specific drug has been previously approved for the COVID-19 treatment. The Lombardy Section of the Italian Society of Infectious and Tropical Diseases provided this <<vademecum>> with the aim to explore the current evidence about the drugs likely to be efficacious in the treatment of COVID-19. Moreover, a multidisciplinary group including critical care specialists has been created in order to provide indications about supporting measures and the use of steroids. A new grading scale has been proposed to help patients' stratification according to the severity of the respiratory conditions. Lastly, a collaborating group with immunologists and rheumatologists has been built with the aim of providing some guidance about the use of tocilizumab, a promising option for the treatment of the hyperinflammatory state occurring in most patients affected by COVID-19."],"journal":"Infez Med","authors":["Lombardy Section Italian Society Infectious And Tropical Diseases, -"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32275256","week":"202015|Apr 06 - Apr 12","source":"PubMed","locations":["Italy","Lombardy","Lombardy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Treatment"],"weight":1,"e_drugs":["tocilizumab","Steroids"],"_version_":1663712077903036416,"score":102.10875},{"pmid":32275287,"title":"COVID-19 in Italy: impact of containment measures and prevalence estimates of infection in the general population.","text":["COVID-19 in Italy: impact of containment measures and prevalence estimates of infection in the general population.","Since the beginning of the COVID-19 epidemic in Italy, the Italian Government implemented several restrictive measures to contain the spread of the infection. Data shows that, among these measures, the lockdown implemented as of 9 March had a positive impact, in particular the central and southern regions of Italy, while other actions appeared to be less effective. When the true prevalence of a disease is unknown, it is possible estimate it, based on mortality data and the assumptive case-fatality rate of the disease. Given these assumptions, the estimated period-prevalence of COVID-19 in Italy varies from 0.35% in Sicity to 13.3% in Lombardy.","Acta Biomed","Signorelli, Carlo","Scognamiglio, Thea","Odone, Anna","32275287"],"abstract":["Since the beginning of the COVID-19 epidemic in Italy, the Italian Government implemented several restrictive measures to contain the spread of the infection. Data shows that, among these measures, the lockdown implemented as of 9 March had a positive impact, in particular the central and southern regions of Italy, while other actions appeared to be less effective. When the true prevalence of a disease is unknown, it is possible estimate it, based on mortality data and the assumptive case-fatality rate of the disease. Given these assumptions, the estimated period-prevalence of COVID-19 in Italy varies from 0.35% in Sicity to 13.3% in Lombardy."],"journal":"Acta Biomed","authors":["Signorelli, Carlo","Scognamiglio, Thea","Odone, Anna"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32275287","week":"202015|Apr 06 - Apr 12","doi":"10.23750/abm.v91i3-S.9511","source":"PubMed","locations":["Italy","Italy","Italy","Lombardy","Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Epidemic Forecasting","Prevention"],"weight":1,"_version_":1663712077910376448,"score":93.76095},{"pmid":32298514,"title":"Non-cutaneous considerations of COVID19 for dermatology practices.","text":["Non-cutaneous considerations of COVID19 for dermatology practices.","COVID19 presents many pressing challenges to the global dermatological community and our patients with ongoing skin needs, which must be considered by every dermatology provider. Many of these are logistical and administrative, distinct from physical manifestations, and could be summarised by the acronym COVID.","J Cosmet Dermatol","Ali, Faisal R","Al-Niaimi, Firas","32298514"],"abstract":["COVID19 presents many pressing challenges to the global dermatological community and our patients with ongoing skin needs, which must be considered by every dermatology provider. Many of these are logistical and administrative, distinct from physical manifestations, and could be summarised by the acronym COVID."],"journal":"J Cosmet Dermatol","authors":["Ali, Faisal R","Al-Niaimi, Firas"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32298514","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jocd.13444","keywords":["COVID19","Coronavirus","dermatology","immunosuppressants","practice management","teledermatology"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664266651317567488,"score":93.3465}]}